MCID: PRP036
MIFTS: 53

Peripheral T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 12 75 53 15 38 72
Peripheral T Cell Lymphoma 37
Lymphoma T-Cell Peripheral 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0050749
KEGG 37 H01892
ICD10 33 C84.4
UMLS 72 C0079774

Summaries for Peripheral T-Cell Lymphoma

KEGG : 37
Peripheral T cell lymphomas (PTCLs) are a group of rare lymphomas originating from mature (i.e., post-thymic or "peripheral") T lymphocytes and NK cells. With regard to the current WHO classification, leukemic, cutaneous, nodal, and extranodal PTCL are distinguished. The most common subtypes worldwide are the nodal T cell lymphomas. In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. Novel approaches are gradually clarifying the molecular pathogenesis of PTCLs. ALK gene translocation and dual specificity phosphatase 22 (DUSP22) gene translocation are seen in ALK-positive ALCL and ALK-negative ALCL, respectively. Recently, gene mutations in epigenetic regulators, including Ten-Eleven Translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), and isocitrate dehydrogenase 1 /2 (IDH1/2), are discovered in hematologic malignancies. The mutation frequencies were especially high in AITL and PTCL-NOS.

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as peripheral t cell lymphoma, is related to anaplastic large cell lymphoma and lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Epirubicin and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and nk cells, and related phenotypes are no effect and Decreased cell migration

Disease Ontology : 12 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.

Wikipedia : 75 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 anaplastic large cell lymphoma 32.4 TNFRSF8 GZMB ALK
2 lymphoma 32.4 TNFRSF8 TCL1A BCL6 ALK
3 lymphoma, hodgkin, classic 31.7 MME BCL6 ALK
4 angioimmunoblastic t-cell lymphoma 31.7 TIA1 TET2 SYK MME ITK GZMB
5 composite lymphoma 31.6 TIA1 GZMB BCL6
6 alk-negative anaplastic large cell lymphoma 31.6 CXCR3 CCR4 ALK
7 hepatosplenic t-cell lymphoma 31.6 TIA1 GZMB
8 diffuse large b-cell lymphoma 31.5 TNFRSF8 MME BCL6
9 panniculitis 31.5 TIA1 NCAM1 GZMB
10 cutaneous t cell lymphoma 31.4 TNFRSF8 TIA1 IL2 GZMB CCR4
11 lymphomatoid granulomatosis 31.3 TIA1 GZMB
12 lethal midline granuloma 31.2 TIA1 NCAM1
13 sezary's disease 31.1 TNFRSF8 IL2 CCR4
14 primary cutaneous anaplastic large cell lymphoma 31.1 TIA1 GZMB ALK
15 mycosis fungoides 31.1 TNFRSF8 TIA1 IL2 GZMB CXCR3 CCR4
16 lymphomatoid papulosis 31.1 TIA1 GZMB ALK
17 colon lymphoma 30.6 TNFRSF8 BCL6 ALK
18 natural killer cell leukemia 30.5 TIA1 NCAM1 GZMB
19 immune deficiency disease 30.5 TNFRSF8 IL2RB IL2
20 reticulosarcoma 30.4 TNFRSF8 TIA1 GZMB BCL6 ALK
21 t-cell large granular lymphocyte leukemia 30.4 NCAM1 IL2 GZMB
22 mantle cell lymphoma 30.4 SYK MME BCL6
23 hemophagocytic lymphohistiocytosis 30.2 ITK IL2RB GZMB
24 pediatric lymphoma 30.1 TNFRSF8 NCAM1 MME ALK
25 lymphoma, mucosa-associated lymphoid type 30.1 MME CXCR3 CXCL13 BCL6
26 lung lymphoma 29.9 TNFRSF8 NCAM1 GZMB BCL6 ALK
27 leukemia, chronic lymphocytic 29.9 TCL1A SYK MS4A1 IL2 CXCR3 BCL6
28 sarcoidosis 1 29.8 TNFRSF8 IL2RB IL2 CXCR3 ALK
29 burkitt lymphoma 29.3 TCL1A MS4A1 MME CXCL13 BCL6
30 hematologic cancer 29.0 TNFRSF8 TET2 SYK NCAM1 MME IL2
31 lymphoma, non-hodgkin, familial 28.4 TNFRSF8 TCL1A SYK MS4A1 MME IL2RB
32 primary cutaneous peripheral t-cell lymphoma not otherwise specified 12.9
33 enteropathy-associated t-cell lymphoma 11.9
34 b-cell lymphoma 10.9
35 neutropenia 10.8
36 t-cell leukemia 10.8
37 leukemia, t-cell, chronic 10.8
38 adult t-cell leukemia 10.7
39 viral esophagitis 10.7 TIA1 GZMB
40 primary cutaneous gamma/delta-positive t-cell lymphoma 10.7
41 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.7
42 lymphocytic gastritis 10.7 TIA1 GZMB
43 hematopoietic stem cell transplantation 10.6
44 fixed drug eruption 10.6 IL2 CCR4
45 lymphocytic leukemia 10.6
46 hypereosinophilic syndrome 10.6
47 heart lymphoma 10.6 MME BCL6
48 t-cell lymphoma, subcutaneous panniculitis-like 10.6
49 splenomegaly 10.6
50 pancytopenia 10.6

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

GenomeRNAi Phenotypes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ALK BCL6 CCR4 CD8A CXCL13 CXCR3
2 Decreased cell migration GR00055-A-1 9.55 ALK ITK NCAM1 RHOA SYK
3 Increased cell migration GR00055-A-3 9.26 ITK NCAM1 RHOA SYK

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 BCL6 CCR4 CD8A CXCL13 CXCR3 IL2
2 endocrine/exocrine gland MP:0005379 10.02 ALK BCL6 CD8A IL2 IL2RB ITK
3 immune system MP:0005387 10 BCL6 CCR4 CD8A CXCL13 CXCR3 IL2
4 liver/biliary system MP:0005370 9.5 BCL6 IL2 IL2RB MME NME1 SYK
5 mortality/aging MP:0010768 9.4 ALK BCL6 CD8A CXCR3 IL2 IL2RB

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
3
Dacarbazine Approved, Investigational Phase 4 4342-03-4 5351166
4
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
5
Busulfan Approved, Investigational Phase 4 55-98-1 2478
6
Infliximab Approved Phase 4 170277-31-3
7
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
8 Antibodies, Blocking Phase 4
9
Apatinib Phase 4 811803-05-1
10 Gastrointestinal Agents Phase 4
11
asparaginase Phase 4
12 Thymoglobulin Phase 4
13 Antilymphocyte Serum Phase 4
14
Vinblastine Approved Phase 3 865-21-4 241903 13342
15
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
16
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
17
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
18
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
19
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
20
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
21
Cobalamin Experimental Phase 3 13408-78-1 6857388
22 glucocorticoids Phase 3
23 Hormones Phase 3
24 Anti-Inflammatory Agents Phase 3
25 Antineoplastic Agents, Hormonal Phase 3
26 Hormone Antagonists Phase 3
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
28 Micronutrients Phase 3
29 Trace Elements Phase 3
30 Hematinics Phase 3
31 Nutrients Phase 3
32 Vitamins Phase 3
33 Vitamin B 12 Phase 3
34 Vitamin B12 Phase 3
35 10-deazaaminopterin Phase 3
36
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
37
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
38
Gemcitabine Approved Phase 2 95058-81-4 60750
39
Mogamulizumab Approved, Investigational Phase 2 1159266-37-1
40
Adenosine Approved, Investigational Phase 2 58-61-7 60961
41
Bevacizumab Approved, Investigational Phase 2 216974-75-3
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 23925 27284
44
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
45
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
46
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
47
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
48
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
49
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2
50
Carmustine Approved, Investigational Phase 1, Phase 2 154-93-8 2578

Interventional clinical trials:

(show top 50) (show all 298)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
2 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Peripheral T-cell Lymphoma Recruiting NCT04040491 Phase 4 PD-1 blocking antibody, chidamide, lenalidomide and etoposide
3 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03631862 Phase 4 Apatinib;CHOP Regimen
4 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
5 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
6 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
7 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
8 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
9 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
10 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
11 Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
12 A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
13 A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas Completed NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
14 Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03952572 Phase 3 Cyclophosphamide;pegylated liposomal doxorubicin;Vincristine;Prednisone;Doxorubicin
15 Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
16 A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma Active, not recruiting NCT03349333 Phase 3 pralatrexate
17 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
18 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
19 Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Not yet recruiting NCT03553537 Phase 3 Decitabine;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
20 A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy Terminated NCT01420679 Phase 3 Pralatrexate Injection
21 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
22 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
23 A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma. Unknown status NCT00211185 Phase 2 ONTAK (denileukin diftitox, DAB389 IL-2)
24 Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma: A Phase II Clinical Trial Unknown status NCT02856997 Phase 2 Chidamide with ICE regimen
25 Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma, a Single-Center, Nonrandomized Phase II Clinical Trial Unknown status NCT02944812 Phase 2 Chidamide
26 A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Unknown status NCT00299351 Phase 2 Depsipeptide
27 Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
28 Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial Unknown status NCT00632827 Phase 2 REGIMEN;REGIMEN B
29 The Efficacy and Toxicity of GDP Chemotherapy in Patients With Peripheral T-cell Lymphoma: An Open-label, Single-arm, Phase II Clinical Trial Unknown status NCT02404571 Phase 2 GDP chemotherapy
30 The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study. Unknown status NCT02520219 Phase 2 GDP
31 Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65 Unknown status NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
32 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
33 Pilot Study of GC. (Gemcitabine-Rituximab-Oxaliplatin Combination) Given Every 14 Days With Maintenance Lenalidomide for the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Unknown status NCT01307592 Phase 2 gemcitabine hydrochloride;lenalidomide;oxaliplatin
34 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
35 Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL Unknown status NCT00840385 Phase 2 FAD
36 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
37 Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation Completed NCT01806337 Phase 2 Alemtuzumab
38 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT02013362 Phase 1, Phase 2 Pralatrexate injection
39 Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients Completed NCT01776411 Phase 1, Phase 2 forodesine hydrochloride
40 Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients. Completed NCT01822886 Phase 2 Romidepsin, Gemcitabine
41 A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT00865969 Phase 2 PXD101
42 A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT00364923 Phase 2 Pralatrexate Injection
43 A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma Completed NCT01456039 Phase 1, Phase 2 Romidepsin
44 Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001 Completed NCT01226472 Phase 2
45 A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma Completed NCT00136565 Phase 2 Velcade;Doxorubicin;Prednisone;Cyclophosphamide;Vindesine;Bleomycin
46 Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Completed NCT01611142 Phase 2
47 A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002) Completed NCT00426764 Phase 2 Romidepsin
48 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
49 A Nordic Phase II Study of Peripheral T-cell Lymphomas Based on Dose-intensive Induction and High-dose Consolidation With Autologous Stem Cell Rescue Completed NCT00791947 Phase 2 CHOEP + G-CSF followed by BEAM
50 Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

41
T Cells, B Cells, Nk Cells, Bone, Thymus, Bone Marrow, Liver

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 2296)
# Title Authors PMID Year
1
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. 9 38
20217288 2010
2
Primary cutaneous follicular variant of peripheral T-cell lymphoma NOS. A report of two cases. 9 38
20459562 2010
3
Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. 9 38
19710685 2010
4
Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. 9 38
19377442 2009
5
[Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis]. 9 38
19575875 2009
6
[Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. 9 38
19575892 2009
7
Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. 9 38
19365529 2009
8
Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation. 9 38
18842429 2009
9
Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. 9 38
18425045 2008
10
[Peripheral T-cell lymphoma, NOS arising in Warthin tumor: report of a case]. 9 38
19031731 2008
11
Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. 9 38
17582237 2007
12
Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. 9 38
17431414 2007
13
[Expression and clinical significance of Mcl-1 in T-cell non-Hodgkin's lymphoma]. 9 38
17430669 2007
14
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 9 38
17430665 2007
15
[Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma]. 9 38
17166378 2006
16
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 9 38
16680156 2006
17
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. 9 38
16341044 2006
18
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. 9 38
16091734 2005
19
Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. 9 38
16160469 2005
20
Peripheral T-cell lymphoma not otherwise specified vs. Hodgkin's lymphoma on fine needle aspiration cytology. 9 38
16124164 2005
21
Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. 9 38
15925824 2005
22
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. 9 38
15514005 2005
23
Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). 9 38
15965283 2005
24
Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. 9 38
15531460 2004
25
CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. 9 38
15328188 2004
26
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. 9 38
15105810 2004
27
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 9 38
15133473 2004
28
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. 9 38
14616965 2003
29
Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. 9 38
12707037 2003
30
CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. 9 38
11979374 2002
31
T-cell receptor Vbeta repertoire in nodal non-anaplastic peripheral T-cell lymphomas. 9 38
12166895 2002
32
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. 9 38
11731410 2001
33
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. 9 38
11222361 2001
34
Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. 9 38
11235901 2001
35
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 9 38
10786666 2000
36
Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. 9 38
10414505 1999
37
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. 9 38
9736036 1998
38
Amplification of the TCL1 flanking region at 14q32.1 with no TCL1 gene transcription in a patient with peripheral T cell lymphoma. 9 38
9639427 1998
39
Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis. 9 38
8655683 1996
40
High-grade pleomorphic T cell lymphoma with restricted involvement of skin and bone marrow. 9 38
8513200 1993
41
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. 9 38
1373974 1992
42
[Midline malignant reticulosis: a histopathological, ultrastructural and immunohistochemical study of 11 cases]. 9 38
1813158 1991
43
Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. 9 38
1652981 1991
44
Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. 38
30890046 2019
45
Canine CD4+ T-cell lymphoma identified by flow cytometry exhibits a consistent histomorphology and gene expression profile. 38
30684308 2019
46
Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. 38
30980412 2019
47
Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype. 38
31283630 2019
48
Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma. 38
31243570 2019
49
Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. 38
31393197 2019
50
RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. 38
31394087 2019

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 TNFRSF8 SYK RHOA ITK IL2RB IL2
2
Show member pathways
13.15 TNFRSF8 RHOA IL2RB IL2 CXCR3 CXCL13
3
Show member pathways
12.74 ITK IL2 GZMB CXCL13 CD8A
4
Show member pathways
12.74 RHOA ITK CXCR3 CXCL13 CCR4
5
Show member pathways
12.41 RHOA ITK IL2 CD8A
6
Show member pathways
12.23 SYK ITK IL2RB IL2
7
Show member pathways
12.12 CXCR3 CXCL13 CCR4
8
Show member pathways
12.06 SYK RHOA ITK CXCR3 CXCL13 CCR4
9
Show member pathways
12.01 SYK RHOA IL2RB IL2
10 11.98 SYK ITK IL2RB ALK
11
Show member pathways
11.92 SYK RHOA IL2RB IL2
12
Show member pathways
11.79 IL2RB IL2 GZMB CD8A
13 11.79 TNFRSF8 SYK NCAM1 ITK IL2RB IL2
14 11.74 MS4A1 MME CD8A
15 11.7 NCAM1 MS4A1 MME IL2RB IL2 CD8A
16 11.52 NCAM1 MS4A1 MME IL2 CD8A
17
Show member pathways
11.49 IL2RB IL2 GZMB CD8A
18 11.39 TNFRSF8 MS4A1 MME BCL6
19 11.34 NCAM1 IL2RB IL2 GZMB CXCR3 CD8A
20 11.12 ITK IL2 CD8A
21
Show member pathways
11.06 SYK IL2RB IL2
22 10.77 RHOA NME1

GO Terms for Peripheral T-Cell Lymphoma

Cellular components related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 MS4A1 MME IL2RB CXCR3 CD8A CCR4
2 T cell receptor complex GO:0042101 9.16 SYK CD8A
3 external side of plasma membrane GO:0009897 9.1 NCAM1 MS4A1 IL2RB CXCR3 CD8A CCR4

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.93 SYK ITK IL2 CD8A BCL6
2 immune response GO:0006955 9.85 IL2 CXCR3 CXCL13 CD8A CCR4
3 negative regulation of apoptotic process GO:0043066 9.83 TCL1A IL2RB IL2 BCL6
4 cell surface receptor signaling pathway GO:0007166 9.81 SYK CXCR3 CXCL13 CD8A
5 cell chemotaxis GO:0060326 9.67 CXCR3 CXCL13 CCR4
6 chemokine-mediated signaling pathway GO:0070098 9.58 CXCR3 CXCL13 CCR4
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 IL2 CXCR3 CXCL13 CCR4
8 positive regulation of regulatory T cell differentiation GO:0045591 9.48 IL2 BCL6
9 positive regulation of alpha-beta T cell differentiation GO:0046638 9.43 SYK RHOA
10 negative regulation of B cell apoptotic process GO:0002903 9.37 IL2 BCL6
11 germinal center formation GO:0002467 9.32 CXCL13 BCL6
12 leukocyte activation involved in immune response GO:0002366 9.16 SYK IL2
13 beta selection GO:0043366 8.96 SYK RHOA
14 interleukin-2-mediated signaling pathway GO:0038110 8.8 SYK IL2RB IL2

Sources for Peripheral T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....